Iwama et al. identified that ipilimumab-induced hypophysitis is likely driven by the direct binding of anti-CTLA-4 antibodies to CTLA-4-expressing pituitary cells, leading to antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-mediated cytotoxicity (CDC) [51]. Here, CTLA4 is linked to hypophysitis.